Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients

被引：0
|
作者：
Zhang, L. [1 ]
Lu, S. [2 ]
Dechaphunkul, A. [3 ]
Chessari, S. [4 ]
Lanzarotti, C. [5 ]
Jordan, K. [6 ]
Aapro, M. [7 ]
机构：
[1] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[3] Prince Songkla Univ, Div Med Oncol, Hat Yai, Thailand
[4] Helsinn Healthcare, Corp Clin Dev, Lugano, Switzerland
[5] Helsinn Healthcare, Stat & Data Management, Lugano, Switzerland
[6] Heidelberg Univ, Dept Med 5, Heidelberg, Germany
[7] Clin Genolier, Multidisciplinary Oncol Inst, Ctr Canc, Genolier, Switzerland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
501O
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
    Aapro, M.
    Rugo, H.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Bondarenko, I.
    Sarosiek, T.
    Oprean, C.
    Cardona-Huerta, S.
    Lorusso, V.
    Karthaus, M.
    Schwartzberg, L.
    Grunberg, S.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1328 - 1333
  • [32] 3-day Aprepitant Plus Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving Cisplatin-based Chemotherapy
    Sym, S. J.
    Hong, J.
    Jung, M.
    Park, J.
    Cho, E. K.
    Lee, J. H.
    Shin, D. B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S245 - S245
  • [33] Phase II Clinical Trial of NEPA (Netupitant/Palonosetron) for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patient Receiving the BEAM Conditioning Regimen
    Bubalo, Joseph
    Chen, Andy I.
    Leong, Kelli
    Gille, Bianca
    Nagle, Sarah
    Bensch, Kenneth
    Macey, Tara
    Ellison, Kelly
    Booth, Georgeann
    Misra, Shikha
    Maziarz, Richard T.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [34] NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron
    Rugo, H. S.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Lorusso, V.
    Karthaus, M.
    Bondarenko, I.
    Sarosiek, T. J.
    Aapro, M. S.
    CANCER RESEARCH, 2013, 73
  • [35] Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy
    Molasiotis, A.
    Aapro, M. S.
    Alonzi, A.
    Chrapava, M.
    Jordan, K.
    Roeland, E. J.
    Schwartzberg, L. S.
    Terrasanta, C.
    Olivari, S.
    Dranitsaris, G.
    ANNALS OF ONCOLOGY, 2022, 33 : 1546 - 1546
  • [36] Assessing the Benefit of NEPA (Fixed Combination of Netupitant/Palonosetron) for preventing Chemotherapy-induced Nausea and Vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy
    Karthaus, M.
    Christoph, D. C.
    Lux, M. P.
    Hofheinz, R. -D
    Jordan, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 252 - 253
  • [37] Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic
    Hesketh, Paul J.
    Palmas, Marco
    Nicolas, Pierre
    SUPPORTIVE CARE IN CANCER, 2018, 26 (04) : 1151 - 1159
  • [38] Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic
    Paul J. Hesketh
    Marco Palmas
    Pierre Nicolas
    Supportive Care in Cancer, 2018, 26 : 1151 - 1159
  • [39] A cost-effective analysis of palonosetron in combination with 3-day corticosteroid for the prevention of chemotherapy-induced nausea and vomiting (CINV) in a private practice office.
    Wong, SF
    Ugai, J
    Quist, R
    PHARMACOTHERAPY, 2005, 25 (10): : 1471 - 1471
  • [40] Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
    Nilsson, Jonas
    Piovesana, Vittoria
    Turini, Marco
    Lezzi, Claudio
    Eriksson, Jennifer
    Aapro, Matti
    SUPPORTIVE CARE IN CANCER, 2022, 30 (11) : 9307 - 9315
12345